BioNotebook: Ten deals and a breakup; Gilead/Ono, Vernalis/Novartis, Sorrento/NantWorks and more

Gilead licenses Ono BTK Inhibitor; Novartis stops developing Vernalis drug; Sorrento partners with NantWorks, Conkwest; Xencor, Novo enter discovery collaboration; ContraVir licenses Chimerix antiviral; MiNa accesses Marina technology; Bayer takes second X-Chem program; Durect grants rights to Santen; Adapt licenses Lightlake's intranasal treatment; and Oncothyreon expands deal with Array.

Gilead licenses Ono BTK Inhibitor; Novartis stops developing Vernalis drug; Sorrento partners with NantWorks, Conkwest; Xencor, Novo enter discovery collaboration; ContraVir licenses Chimerix antiviral; MiNa accesses Marina technology; Bayer takes second X-Chem program; Durect grants rights to Santen; Adapt licenses Lightlake's intranasal treatment; and Oncothyreon expands deal with Array.

'Tis the season to sign (or break) deals

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category